ASM Joins Global One Health Diagnostics Access Compact
April 7, 2026
Lyon, France-A coalition of more than 20 international partners announced the Global One Health Diagnostics Access Compact (GO-Dx) during the
G7 One Health Summit in Lyon, France. This new initiative serves as a catalyst for international leaders across different sectors to advance progress toward expanding diagnostics access, enabling early detection and better surveillance, and improving response against existing and emerging threats across human, animal and environmental health. By aligning efforts, this group aims to strengthen global preparedness through science-based One Health solutions.
Around the world, health authorities are struggling to keep pace with increasingly interconnected threats-from climate-driven shifts that expand the spread of disease carrying species, to rising cases of diseases spilling over from animals to humans and worsening antimicrobial resistance (AMR). In many regions, the basic ability to test bacteria and other pathogens is scarce or non-existent with information across human, animal and environmental health remaining siloed and slowing detection. The result is delayed diagnosis, inappropriate treatment, avoidable antibiotic use, compromised patient outcomes and slower recognition of new pathogens and outbreaks.
As countries refine AMR strategies and prepare upcoming G7 and multilateral commitments, the need for practical, collaborative action is urgent. It is in this context that these partners have developed the GO-Dx Compact-a collective effort to close diagnostic gaps, align action across sectors and support countries in building more resilient, intelligence-driven health systems.
GO-Dx Compact marks a critical, multi-stakeholder step across the One Health interface toward prioritizing diagnostics access and innovation, bolstering surveillance and driving antimicrobial stewardship through education and training. By aligning with national and international policy frameworks and advocating for increased public-private collaboration, the Compact aims to increase accurate treatment, reinforce infection-prevention strategies, fortify health systems and address the rising threat of AMR and other existing and emerging threats.
GO-Dx Partners and Commitments
The Compact is being advanced by a diverse group of partners spanning civil society, private sector, professional and scientific societies, foundations and global health initiatives committed to One Health and AMR action. Together, they represent tens of thousands of infectious disease and microbiology professionals and support diagnostic, prevention and treatment pathways that reach tens to hundreds of millions of patients each year across health systems in more than 130 countries (find the complete signatories list below).
By endorsing the Compact, the signatories collectively commit to advancing 4 pillars:
-
Improved Access to Appropriate, High-Quality Diagnostics for All: expand affordable access to priority diagnostics across levels of care and geographies; support data and knowledge sharing to inform public health action.
-
Strengthened Stewardship and Appropriate Use of Diagnostics and Antibiotics: link access to last-line antibiotics with increased diagnostic utilization; integrate diagnostic algorithms and context-relevant AMS training to reinforce diagnostic led decision making.
-
Investment in R&D to Meet Public Health Needs: advance innovation for human, animal and environmental diagnostics, including solutions contextualized for resource limited settings, through public-private partnerships and open collaboration across industry, academia, NGOs and public partners.
-
Improved Valuation and Integration of Diagnostics: work with governments, payers and global partners to ensure diagnostics are appropriately valued, reimbursed and integrated into clinical and public-health pathways, as well as in animal-health settings, reflecting downstream benefits such as reduced antimicrobial consumption and cost savings.
GO-Dx Compact Next Steps
The Compact signatories commit to advancing this shared effort, recognizing that specific contributions will vary according to individual missions, business models and areas of work. Each organization will take forward the elements most aligned with its strategic focus while upholding the shared intent of advancing access, stewardship, innovation and appropriate valuation of diagnostics. Where appropriate, organizations will engage with national governments and multilateral processes, including the G7, to support progress and help ensure diagnostics and surveillance are more systematically reflected in policy commitments, funding mechanisms and global health strategies.
Full Partner List:
African Society for Laboratory Medicine
American Society for Microbiology
AMR Action Fund
Bavarian Nordic
bioMérieux
British Society for Antimicrobial Chemotherapy
CARB-X
Ceva Animal Health
Copan Group
Danaher Corporation
DxAMR Collaborative
European Society of Clinical Microbiology and Infectious Diseases
Infectious Diseases Society of America
InnotiveDx
International Society of Antimicrobial Chemotherapy
LifeArc
Liofilchem
Nostics
Novo Nordisk Foundation
Roche Diagnostics
Sysmex
Waters Corporation
###
The American Society for Microbiology is one of the largest professional societies dedicated to the life sciences and is composed of over 38,000 scientists and health practitioners. ASM's mission is to promote and advance the microbial sciences.
ASM advances the microbial sciences through conferences, publications, certifications, educational opportunities and advocacy efforts. It enhances laboratory capacity around the globe through training and resources. It provides a network for scientists in academia, industry and clinical settings. Additionally, ASM promotes a deeper understanding of the microbial sciences to all audiences.